NPM1
Common AML mutation, generally favorable prognosis when isolated. Drives sensitivity to menin inhibitors and venetoclax.
No Clinical Trials found for this biomarker.
Common AML mutation, generally favorable prognosis when isolated. Drives sensitivity to menin inhibitors and venetoclax.
No Clinical Trials found for this biomarker.